1. Masdeu, J.C., Gadhia, R., Faridar, A. Brain CT and MRI: differential diagnosis of imaging findings. Handb. Clin. Neurol. 136, 1037-54 (2016).
2. Al-Okaili, R.N. et al. Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience. Radiology. 243, 539-50 (2007).
3. Hardy, T.A. Pseudotumoral demyelinating lesions: diagnostic approach and long-term outcome. Curr. Opin. Neurol. 32, 467-74 (2019).
4. Renard, D., Castelnovo, G., Le Floch, A., Guillamo, J.S., Thouvenot, E. Pseudotumoral brain lesions: MRI review. Acta Neurol. Belg. 117, 17-26 (2017).
5. Law, L.Y., Riminton DS, Nguyen M, Barnett MH, Reddel SW, Hardy TA. The spectrum of immune-mediated and inflammatory lesions of the brainstem: clues to diagnosis. Neurology. 93, 390-405 (2019).
6. Weller, M. et al. Glioma. Nat. Rev. Dis. Primers. 1, 15017; 10.1038/nrdp.2015.17 (2015).
7. Glaudemans AW et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur. J. Nucl. Med. Mol. Imaging. 40, 615-635 (2013).
8. de Zwart, P.L. et al. Diagnostic accuracy of PET tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and metaanalysis. J. Nucl. Med. 61, 498-504 (2020).
9. Treglia, G. et al. Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta-analyses. Int. J. Mol. Sci. 20, 4669; 10.3390/ijms20194669 (2019).
10. Falk Delgado, A., Falk Delgado, A. Discrimination between primary low-grade and high-grade glioma with 11 C-methionine PET: a bivariate diagnostic test accuracy meta-analysis. Br. J. Radiol. 1082, 20170426; 10.1259/bjr.20170426 (2018).
11. Katsanos, A.H., Alexiou, G.A., Fotopoulos, A.D., Jabbour, P., Kyritsis, A.P., Sioka, C. Performance of 18F-FDG, 11C-methionine, and 18F-FET PET for glioma grading: a meta-analysis. Clin. Nucl. Med. 44, 864-869 (2019).
12. Wang Y. et al. 11C methionine PET (MET-PET) Imaging of glioblastoma for detecting postoperative residual disease and response to chemoradiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 102, 1024-1028 (2018).
13. Takenaka, S. et al. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir (Tokyo). 54, 280-289 (2014).
14. Kits, A., Martin, H., Sanchez-Crespo, A., Delgado, A.F. Diagnostic accuracy of 11 C-methionine PET in detecting neuropathologically confirmed recurrent brain tumor after radiation therapy. Ann. Nucl. Med. 32, 132-141 (2018).
15. Terakawa, Y. et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J. Nucl. Med. 49, 694-699 (2008).
16. Galldiks, N. et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur. J. Nucl. Med. Mol. Imaging. 33, 516-524 (2006).
17. Glaudemans, A.W. et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur. J. Nucl. Med. Mol. Imaging. 40, 615-635 (2013).
18. Hotta, M., Minamimoto, R., Miwa, K. 11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier. Sci Rep. 9, 15666; 10.1038/s41598-019-52279-2 (2019).
19. Iwadate, Y., Shinozaki, N., Matsutani, T., Uchino, Y., Saeki, N. Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography. J. Neurol. Neurosurg. Psychiatry. 87, 1016-1021 (2016).
20. Ishiwata, K., Ido, T., Abe, Y., Matsuzawa, T., Iwata, R. Tumor uptake studies of S-adenosyl-L-[methyl-11C]methionine and L-[methyl-11C]methionine. Int. J. Rad. Appl. Instrum. B. 15, 123-126 (1988).
21. Akamatsu, G. et al. Influence of statistical fluctuation on reproducibility and accuracy of SUVmax and SUVpeak: a phantom study. J. Nucl. Med. Technol. 43, 222-226 (2015).
22. Youden. W.J. Index for rating diagnostic tests. Cancer. 3, 32-35 (1950).
23. Herholz, K. et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 50, 1316-1322 (1998).
24. Renard, D. et al. 18 F-FDOPA-PET in pseudotumoral brain lesions. J. Neurol. 268, 1266-1275 (2021).
25. Okubo, S., Zhen, H.N., Kawai, N., Nishiyama, Y., Haba, R., Tamiya, T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J. Neurooncol. 99, 217-225 (2010).
26. Pasternak, K.A. et al. Evaluation of 311 contemporary cases of stereotactic biopsies in patients with neoplastic and non-neoplastic lesions-diagnostic yield and management of non-diagnostic cases. Neurosurg. Rev. 10.1007/s10143-020-01394-0 (2020).
27. Jagannathan, J. et al. Clinical and pathological characteristics of brain metastasis resected after failed radiosurgery. Neurosurgery. 66, 208-217 (2010).
28. Nakajima, R., Kimura, K., Abe, K., Sakai, S. (11)C-methionine PET/CT findings in benign brain disease. Jpn. J. Radiol. 35, 279-288 (2017).
29. Lapa, C. et al. Comparison of 11C-choline and 11C-methionine PET/CT in multiple myeloma. Clin. Nucl. Med. 44, 620-624 (2019).
30. Lapa, C. et al. 11C-Methionine-PET in multiple myeloma: a combined study from two different institutions. Theranostics. 7, 2956-2964 (2017).
31. Kircher, S. et al. Hexokinase-2 Expression in 11C-methionine-positive, 18F-FDG-negative multiple myeloma. J. Nucl. Med. 60, 348-352 (2019).
32. Zaharchuk, G., Davidzon, G. Artificial intelligence for optimization and interpretation of PET/CT and PET/MR images. Semin, Nucl, Med. 51, 134-142 (2021).
33. Seifert, R., Weber, M., Kocakavuk, E., Rischpler, C., Kersting, D. Artificial intelligence and machine learning in nuclear medicine: future perspective. Semin. Nucl. Med. 51, 170-177 (2021).
34. Liu, X., Chen, K., Wu, T., Weidman, D., Lure, F., Li, J. Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease. Transl. Res. 194, 56-67 (2018).
35. Tanno, R. et al. Uncertainty modelling in deep learning for safer neuroimage enhancement: Demonstration in diffusion MRI. Neuroimage. 225, 117366; 10.1016/j.neuroimage.2020.117366 (2021).
36. D'Souza, M.M. et al. Metabolic assessment of intracranial tuberculomas using 11C-methionine and 18F-FDG PET/CT. Nucl. Med. Commun. 33, 408-414 (2012).
37. Ng, D., Jacobs, M., Mantil, J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin. Nucl. Med. 31, 373-375 (2006).